Cargando…

Clinical phenotypes and outcomes associated with SARS-CoV-2 Omicron variants BA.2, BA.5 and BQ.1.1 in critically ill patients with COVID-19: a prospective, multicenter cohort study

BACKGROUND: Despite current broad natural and vaccine-induced protection, a substantial number of patients infected with emerging SARS-CoV-2 variants (e.g., BF.7 and BQ.1.1) still experience severe COVID-19. Real-life studies investigating the impact of these variants on clinical outcomes of severe...

Descripción completa

Detalles Bibliográficos
Autores principales: de Prost, Nicolas, Audureau, Etienne, Préau, Sébastien, Favory, Raphaël, Guigon, Aurélie, Bay, Pierre, Heming, Nicholas, Gault, Elyanne, Pham, Tài, Chaghouri, Amal, Voiriot, Guillaume, Morand-Joubert, Laurence, Jochmans, Sébastien, Pitsch, Aurélia, Meireles, Sylvie, Contou, Damien, Henry, Amandine, Joseph, Adrien, Chaix, Marie-Laure, Uhel, Fabrice, Descamps, Diane, Emery, Malo, Garcia-Sanchez, Claudio, Luyt, Charles-Edouard, Marot, Stéphane, Pène, Frédéric, Lhonneur, Anne-Sophie, Gaudry, Stéphane, Brichler, Ségolène, Picard, Lucile, Mekontso Dessap, Armand, Rodriguez, Christophe, Pawlotsky, Jean-Michel, Fourati, Slim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404579/
https://www.ncbi.nlm.nih.gov/pubmed/37544942
http://dx.doi.org/10.1186/s40635-023-00536-0
_version_ 1785085330353815552
author de Prost, Nicolas
Audureau, Etienne
Préau, Sébastien
Favory, Raphaël
Guigon, Aurélie
Bay, Pierre
Heming, Nicholas
Gault, Elyanne
Pham, Tài
Chaghouri, Amal
Voiriot, Guillaume
Morand-Joubert, Laurence
Jochmans, Sébastien
Pitsch, Aurélia
Meireles, Sylvie
Contou, Damien
Henry, Amandine
Joseph, Adrien
Chaix, Marie-Laure
Uhel, Fabrice
Descamps, Diane
Emery, Malo
Garcia-Sanchez, Claudio
Luyt, Charles-Edouard
Marot, Stéphane
Pène, Frédéric
Lhonneur, Anne-Sophie
Gaudry, Stéphane
Brichler, Ségolène
Picard, Lucile
Mekontso Dessap, Armand
Rodriguez, Christophe
Pawlotsky, Jean-Michel
Fourati, Slim
author_facet de Prost, Nicolas
Audureau, Etienne
Préau, Sébastien
Favory, Raphaël
Guigon, Aurélie
Bay, Pierre
Heming, Nicholas
Gault, Elyanne
Pham, Tài
Chaghouri, Amal
Voiriot, Guillaume
Morand-Joubert, Laurence
Jochmans, Sébastien
Pitsch, Aurélia
Meireles, Sylvie
Contou, Damien
Henry, Amandine
Joseph, Adrien
Chaix, Marie-Laure
Uhel, Fabrice
Descamps, Diane
Emery, Malo
Garcia-Sanchez, Claudio
Luyt, Charles-Edouard
Marot, Stéphane
Pène, Frédéric
Lhonneur, Anne-Sophie
Gaudry, Stéphane
Brichler, Ségolène
Picard, Lucile
Mekontso Dessap, Armand
Rodriguez, Christophe
Pawlotsky, Jean-Michel
Fourati, Slim
author_sort de Prost, Nicolas
collection PubMed
description BACKGROUND: Despite current broad natural and vaccine-induced protection, a substantial number of patients infected with emerging SARS-CoV-2 variants (e.g., BF.7 and BQ.1.1) still experience severe COVID-19. Real-life studies investigating the impact of these variants on clinical outcomes of severe cases are currently not available. We performed a prospective multicenter observational cohort study. Adult patients with acute respiratory failure admitted between December 7, 2021 and December 15, 2022, in one of the 20 participating intensive care units (17 from the Greater Paris area and 3 from the North of France) were eligible for inclusion if they had SARS-CoV-2 infection confirmed by a positive reverse transcriptase-polymerase chain reaction (RT-PCR). Full-length SARS-CoV-2 genomes from all included patients were sequenced by means of next-generation sequencing. The primary endpoint of the study was day-28 mortality. RESULTS: The study included 158 patients infected with three groups of Omicron sublineages, including (i) BA.2 variants and their early sublineages referred as “BA.2” (n = 50), (ii) early BA.4 and BA.5 sublineages (including BA.5.1 and BA.5.2, n = 61) referred as “BA.4/BA.5”, and (iii) recent emerging BA.5 sublineages (including BQ.1, BQ.1.1, BF.7, BE.1 and CE.1, n = 47) referred as “BQ.1.1”. The clinical phenotype of BQ1.1-infected patients compared to earlier BA.2 and BA.4/BA.5 sublineages, showed more frequent obesity and less frequent immunosuppression. There was no significant difference between Omicron sublineage groups regarding the severity of the disease at ICU admission, need for organ failure support during ICU stay, nor day 28 mortality (21.7%, n = 10/47 in BQ.1.1 group vs 26.7%, n = 16/61 in BA.4/BA.5 vs 22.0%, n = 11/50 in BA.2, p = 0.791). No significant relationship was found between any SARS-CoV-2 substitution and/or deletion on the one hand and survival on the other hand over hospital follow-up. CONCLUSIONS: Critically-ill patients with Omicron BQ.1.1 infection showed a different clinical phenotype than other patients infected with earlier Omicron sublineage but no day-28 mortality difference. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40635-023-00536-0.
format Online
Article
Text
id pubmed-10404579
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-104045792023-08-08 Clinical phenotypes and outcomes associated with SARS-CoV-2 Omicron variants BA.2, BA.5 and BQ.1.1 in critically ill patients with COVID-19: a prospective, multicenter cohort study de Prost, Nicolas Audureau, Etienne Préau, Sébastien Favory, Raphaël Guigon, Aurélie Bay, Pierre Heming, Nicholas Gault, Elyanne Pham, Tài Chaghouri, Amal Voiriot, Guillaume Morand-Joubert, Laurence Jochmans, Sébastien Pitsch, Aurélia Meireles, Sylvie Contou, Damien Henry, Amandine Joseph, Adrien Chaix, Marie-Laure Uhel, Fabrice Descamps, Diane Emery, Malo Garcia-Sanchez, Claudio Luyt, Charles-Edouard Marot, Stéphane Pène, Frédéric Lhonneur, Anne-Sophie Gaudry, Stéphane Brichler, Ségolène Picard, Lucile Mekontso Dessap, Armand Rodriguez, Christophe Pawlotsky, Jean-Michel Fourati, Slim Intensive Care Med Exp Research Articles BACKGROUND: Despite current broad natural and vaccine-induced protection, a substantial number of patients infected with emerging SARS-CoV-2 variants (e.g., BF.7 and BQ.1.1) still experience severe COVID-19. Real-life studies investigating the impact of these variants on clinical outcomes of severe cases are currently not available. We performed a prospective multicenter observational cohort study. Adult patients with acute respiratory failure admitted between December 7, 2021 and December 15, 2022, in one of the 20 participating intensive care units (17 from the Greater Paris area and 3 from the North of France) were eligible for inclusion if they had SARS-CoV-2 infection confirmed by a positive reverse transcriptase-polymerase chain reaction (RT-PCR). Full-length SARS-CoV-2 genomes from all included patients were sequenced by means of next-generation sequencing. The primary endpoint of the study was day-28 mortality. RESULTS: The study included 158 patients infected with three groups of Omicron sublineages, including (i) BA.2 variants and their early sublineages referred as “BA.2” (n = 50), (ii) early BA.4 and BA.5 sublineages (including BA.5.1 and BA.5.2, n = 61) referred as “BA.4/BA.5”, and (iii) recent emerging BA.5 sublineages (including BQ.1, BQ.1.1, BF.7, BE.1 and CE.1, n = 47) referred as “BQ.1.1”. The clinical phenotype of BQ1.1-infected patients compared to earlier BA.2 and BA.4/BA.5 sublineages, showed more frequent obesity and less frequent immunosuppression. There was no significant difference between Omicron sublineage groups regarding the severity of the disease at ICU admission, need for organ failure support during ICU stay, nor day 28 mortality (21.7%, n = 10/47 in BQ.1.1 group vs 26.7%, n = 16/61 in BA.4/BA.5 vs 22.0%, n = 11/50 in BA.2, p = 0.791). No significant relationship was found between any SARS-CoV-2 substitution and/or deletion on the one hand and survival on the other hand over hospital follow-up. CONCLUSIONS: Critically-ill patients with Omicron BQ.1.1 infection showed a different clinical phenotype than other patients infected with earlier Omicron sublineage but no day-28 mortality difference. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40635-023-00536-0. Springer International Publishing 2023-08-07 /pmc/articles/PMC10404579/ /pubmed/37544942 http://dx.doi.org/10.1186/s40635-023-00536-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Articles
de Prost, Nicolas
Audureau, Etienne
Préau, Sébastien
Favory, Raphaël
Guigon, Aurélie
Bay, Pierre
Heming, Nicholas
Gault, Elyanne
Pham, Tài
Chaghouri, Amal
Voiriot, Guillaume
Morand-Joubert, Laurence
Jochmans, Sébastien
Pitsch, Aurélia
Meireles, Sylvie
Contou, Damien
Henry, Amandine
Joseph, Adrien
Chaix, Marie-Laure
Uhel, Fabrice
Descamps, Diane
Emery, Malo
Garcia-Sanchez, Claudio
Luyt, Charles-Edouard
Marot, Stéphane
Pène, Frédéric
Lhonneur, Anne-Sophie
Gaudry, Stéphane
Brichler, Ségolène
Picard, Lucile
Mekontso Dessap, Armand
Rodriguez, Christophe
Pawlotsky, Jean-Michel
Fourati, Slim
Clinical phenotypes and outcomes associated with SARS-CoV-2 Omicron variants BA.2, BA.5 and BQ.1.1 in critically ill patients with COVID-19: a prospective, multicenter cohort study
title Clinical phenotypes and outcomes associated with SARS-CoV-2 Omicron variants BA.2, BA.5 and BQ.1.1 in critically ill patients with COVID-19: a prospective, multicenter cohort study
title_full Clinical phenotypes and outcomes associated with SARS-CoV-2 Omicron variants BA.2, BA.5 and BQ.1.1 in critically ill patients with COVID-19: a prospective, multicenter cohort study
title_fullStr Clinical phenotypes and outcomes associated with SARS-CoV-2 Omicron variants BA.2, BA.5 and BQ.1.1 in critically ill patients with COVID-19: a prospective, multicenter cohort study
title_full_unstemmed Clinical phenotypes and outcomes associated with SARS-CoV-2 Omicron variants BA.2, BA.5 and BQ.1.1 in critically ill patients with COVID-19: a prospective, multicenter cohort study
title_short Clinical phenotypes and outcomes associated with SARS-CoV-2 Omicron variants BA.2, BA.5 and BQ.1.1 in critically ill patients with COVID-19: a prospective, multicenter cohort study
title_sort clinical phenotypes and outcomes associated with sars-cov-2 omicron variants ba.2, ba.5 and bq.1.1 in critically ill patients with covid-19: a prospective, multicenter cohort study
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404579/
https://www.ncbi.nlm.nih.gov/pubmed/37544942
http://dx.doi.org/10.1186/s40635-023-00536-0
work_keys_str_mv AT deprostnicolas clinicalphenotypesandoutcomesassociatedwithsarscov2omicronvariantsba2ba5andbq11incriticallyillpatientswithcovid19aprospectivemulticentercohortstudy
AT audureauetienne clinicalphenotypesandoutcomesassociatedwithsarscov2omicronvariantsba2ba5andbq11incriticallyillpatientswithcovid19aprospectivemulticentercohortstudy
AT preausebastien clinicalphenotypesandoutcomesassociatedwithsarscov2omicronvariantsba2ba5andbq11incriticallyillpatientswithcovid19aprospectivemulticentercohortstudy
AT favoryraphael clinicalphenotypesandoutcomesassociatedwithsarscov2omicronvariantsba2ba5andbq11incriticallyillpatientswithcovid19aprospectivemulticentercohortstudy
AT guigonaurelie clinicalphenotypesandoutcomesassociatedwithsarscov2omicronvariantsba2ba5andbq11incriticallyillpatientswithcovid19aprospectivemulticentercohortstudy
AT baypierre clinicalphenotypesandoutcomesassociatedwithsarscov2omicronvariantsba2ba5andbq11incriticallyillpatientswithcovid19aprospectivemulticentercohortstudy
AT hemingnicholas clinicalphenotypesandoutcomesassociatedwithsarscov2omicronvariantsba2ba5andbq11incriticallyillpatientswithcovid19aprospectivemulticentercohortstudy
AT gaultelyanne clinicalphenotypesandoutcomesassociatedwithsarscov2omicronvariantsba2ba5andbq11incriticallyillpatientswithcovid19aprospectivemulticentercohortstudy
AT phamtai clinicalphenotypesandoutcomesassociatedwithsarscov2omicronvariantsba2ba5andbq11incriticallyillpatientswithcovid19aprospectivemulticentercohortstudy
AT chaghouriamal clinicalphenotypesandoutcomesassociatedwithsarscov2omicronvariantsba2ba5andbq11incriticallyillpatientswithcovid19aprospectivemulticentercohortstudy
AT voiriotguillaume clinicalphenotypesandoutcomesassociatedwithsarscov2omicronvariantsba2ba5andbq11incriticallyillpatientswithcovid19aprospectivemulticentercohortstudy
AT morandjoubertlaurence clinicalphenotypesandoutcomesassociatedwithsarscov2omicronvariantsba2ba5andbq11incriticallyillpatientswithcovid19aprospectivemulticentercohortstudy
AT jochmanssebastien clinicalphenotypesandoutcomesassociatedwithsarscov2omicronvariantsba2ba5andbq11incriticallyillpatientswithcovid19aprospectivemulticentercohortstudy
AT pitschaurelia clinicalphenotypesandoutcomesassociatedwithsarscov2omicronvariantsba2ba5andbq11incriticallyillpatientswithcovid19aprospectivemulticentercohortstudy
AT meirelessylvie clinicalphenotypesandoutcomesassociatedwithsarscov2omicronvariantsba2ba5andbq11incriticallyillpatientswithcovid19aprospectivemulticentercohortstudy
AT contoudamien clinicalphenotypesandoutcomesassociatedwithsarscov2omicronvariantsba2ba5andbq11incriticallyillpatientswithcovid19aprospectivemulticentercohortstudy
AT henryamandine clinicalphenotypesandoutcomesassociatedwithsarscov2omicronvariantsba2ba5andbq11incriticallyillpatientswithcovid19aprospectivemulticentercohortstudy
AT josephadrien clinicalphenotypesandoutcomesassociatedwithsarscov2omicronvariantsba2ba5andbq11incriticallyillpatientswithcovid19aprospectivemulticentercohortstudy
AT chaixmarielaure clinicalphenotypesandoutcomesassociatedwithsarscov2omicronvariantsba2ba5andbq11incriticallyillpatientswithcovid19aprospectivemulticentercohortstudy
AT uhelfabrice clinicalphenotypesandoutcomesassociatedwithsarscov2omicronvariantsba2ba5andbq11incriticallyillpatientswithcovid19aprospectivemulticentercohortstudy
AT descampsdiane clinicalphenotypesandoutcomesassociatedwithsarscov2omicronvariantsba2ba5andbq11incriticallyillpatientswithcovid19aprospectivemulticentercohortstudy
AT emerymalo clinicalphenotypesandoutcomesassociatedwithsarscov2omicronvariantsba2ba5andbq11incriticallyillpatientswithcovid19aprospectivemulticentercohortstudy
AT garciasanchezclaudio clinicalphenotypesandoutcomesassociatedwithsarscov2omicronvariantsba2ba5andbq11incriticallyillpatientswithcovid19aprospectivemulticentercohortstudy
AT luytcharlesedouard clinicalphenotypesandoutcomesassociatedwithsarscov2omicronvariantsba2ba5andbq11incriticallyillpatientswithcovid19aprospectivemulticentercohortstudy
AT marotstephane clinicalphenotypesandoutcomesassociatedwithsarscov2omicronvariantsba2ba5andbq11incriticallyillpatientswithcovid19aprospectivemulticentercohortstudy
AT penefrederic clinicalphenotypesandoutcomesassociatedwithsarscov2omicronvariantsba2ba5andbq11incriticallyillpatientswithcovid19aprospectivemulticentercohortstudy
AT lhonneurannesophie clinicalphenotypesandoutcomesassociatedwithsarscov2omicronvariantsba2ba5andbq11incriticallyillpatientswithcovid19aprospectivemulticentercohortstudy
AT gaudrystephane clinicalphenotypesandoutcomesassociatedwithsarscov2omicronvariantsba2ba5andbq11incriticallyillpatientswithcovid19aprospectivemulticentercohortstudy
AT brichlersegolene clinicalphenotypesandoutcomesassociatedwithsarscov2omicronvariantsba2ba5andbq11incriticallyillpatientswithcovid19aprospectivemulticentercohortstudy
AT picardlucile clinicalphenotypesandoutcomesassociatedwithsarscov2omicronvariantsba2ba5andbq11incriticallyillpatientswithcovid19aprospectivemulticentercohortstudy
AT mekontsodessaparmand clinicalphenotypesandoutcomesassociatedwithsarscov2omicronvariantsba2ba5andbq11incriticallyillpatientswithcovid19aprospectivemulticentercohortstudy
AT rodriguezchristophe clinicalphenotypesandoutcomesassociatedwithsarscov2omicronvariantsba2ba5andbq11incriticallyillpatientswithcovid19aprospectivemulticentercohortstudy
AT pawlotskyjeanmichel clinicalphenotypesandoutcomesassociatedwithsarscov2omicronvariantsba2ba5andbq11incriticallyillpatientswithcovid19aprospectivemulticentercohortstudy
AT fouratislim clinicalphenotypesandoutcomesassociatedwithsarscov2omicronvariantsba2ba5andbq11incriticallyillpatientswithcovid19aprospectivemulticentercohortstudy
AT clinicalphenotypesandoutcomesassociatedwithsarscov2omicronvariantsba2ba5andbq11incriticallyillpatientswithcovid19aprospectivemulticentercohortstudy